(3R)-1,4-bis<(methylsulfonyl)oxy>-2,2-dimethyl-3-hydroxybutane | 144043-22-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机磺酸及其衍生物
• 英文名称: (3R)-1,4-bis<(methylsulfonyl)oxy>-2,2-dimethyl-3-hydroxybutane
• 英文别名: [(2R)-2-hydroxy-3,3-dimethyl-4-methylsulfonyloxybutyl] methanesulfonate
• CAS: 144043-22-1
• 化学式: C₈H₁₈O₇S₂
• 分子量: 290.359
• InChiKey: YPKWEVDJNIRMMT-ZETCQYMHSA-N

物化性质

• 沸点：
  525.3±45.0 °C(Predicted)
• 密度：
  1.361±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  17
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  124
• 氢给体数：
  1
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  (3R)-1,4-bis<(methylsulfonyl)oxy>-2,2-dimethyl-3-hydroxybutane 在 吡啶 、 sodium azide 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 (3S)-N-benzyl-3-azido-4,4-dimethylpyrrolidine
  参考文献：
  名称：

  Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones

  摘要：

  A series of novel 7-substituted-1-tert-butyl-6-fluoronaphthyridone-3-carboxylic acids has been prepared. These derivatives are characterized by chiral aminopyrrolidine substituents at the 7 position. In this paper we report the full details of the asymmetric synthesis of this series of compounds. Structure-activity relationship studies indicate that the absolute stereochemistry at the asymmetric centers of the pyrrolidine ring is critical for maintaining good activity. Compounds 60 and 61 (3-amino-4-methylpyrrolidine enantiomers) were selected for preclinical evaluation.

  DOI：

  10.1021/jm00100a028
• 作为产物：
  描述：

  (2R)-(-)-3,3-dimethylbutane-1,2,4-triol 、 甲基磺酰氯 在 吡啶 作用下， 生成 (3R)-1,4-bis<(methylsulfonyl)oxy>-2,2-dimethyl-3-hydroxybutane
  参考文献：
  名称：

  Fluoronaphthyridines and -quinolones as antibacterial agents. 5. Synthesis and antimicrobial activity of chiral 1-tert-butyl-6-fluoro-7-substituted-naphthyridones

  摘要：

  A series of novel 7-substituted-1-tert-butyl-6-fluoronaphthyridone-3-carboxylic acids has been prepared. These derivatives are characterized by chiral aminopyrrolidine substituents at the 7 position. In this paper we report the full details of the asymmetric synthesis of this series of compounds. Structure-activity relationship studies indicate that the absolute stereochemistry at the asymmetric centers of the pyrrolidine ring is critical for maintaining good activity. Compounds 60 and 61 (3-amino-4-methylpyrrolidine enantiomers) were selected for preclinical evaluation.

  DOI：

  10.1021/jm00100a028

文献信息

• Derivatives of 1-(oxoaminoacetyl) pentylcarbamate as cathepsin k inhibitors for the treatment of bone loss
  申请人：Barrett Gene David

  公开号：US20050245596A1

  公开（公告）日：2005-11-03

  Heterocycle substituted ketoamide derivatives of Formula (I), wherein the substitutes A, D, A and R are defined as in claim in, which are useful as cathepsin K inhibitors are described herein. The described invention also includes methods of making such heterocycle substituted ketoamide derivatives as well as method of using the same in the manufacture of medicaments for the treatment of disorders, including osteoporosis, associated with an imbalance between bone resorption and formation which can ultimately lead to fracture.

  本文描述了公式(I)的杂环取代酮酰胺衍生物，其中替代基A、D、A和R如权利要求中所定义，这些衍生物可用作卡特普西林K抑制剂。所述发明还包括制备这种杂环取代酮酰胺衍生物的方法，以及使用它们制造治疗与骨吸收和形成失衡有关的疾病（例如骨质疏松症），最终可能导致骨折的药物的方法。
• Propylcarbamate derivatives as inhibitors of serine and cysteine proteases
  申请人：Deaton Norman David

  公开号：US20050043368A1

  公开（公告）日：2005-02-24

  The present invention includes ketone derivatives (I) and (II), which are useful as cathepsin K inhibitors. The described invention also includes methods of making such ketone derivatives as well as methods of using the same in the treatment of disorders, including osteoporosis.

  本发明涉及酮衍生物（I）和（II），其作为猫hepsin K抑制剂具有用途。所述发明还包括制备此类酮衍生物的方法，以及使用它们治疗疾病的方法，包括骨质疏松症。
• PROPYLCARBAMATE DERIVATIVES AS INHIBITORS OF SERINE AND CYSTEINE PROTEASES
  申请人：SmithKline Beecham Corporation

  公开号：EP1448554A1

  公开（公告）日：2004-08-25
• DERIVATIVES OF 1-(OXOAMINOACETYL) PENTYLCARBAMATE AS CATHEPSIN K INHIBITORS FOR THE TREATMENT OF BONE LOSS
  申请人：SmithKline Beecham Corporation

  公开号：EP1494663A1

  公开（公告）日：2005-01-12
• US7288541B2
  申请人：——

  公开号：US7288541B2

  公开（公告）日：2007-10-30